tiprankstipranks
Trending News
More News >
Benchmark Holdings PLC (GB:BMK)
LSE:BMK
Advertisement

Benchmark Holdings (BMK) AI Stock Analysis

Compare
4 Followers

Top Page

GB:BMK

Benchmark Holdings

(LSE:BMK)

Rating:54Neutral
Price Target:
23.50p
▲(14.91%Upside)
The overall stock score reflects mixed financial performance and a bearish technical outlook, offset by positive corporate events that suggest potential future growth. While operational challenges persist, strategic changes and shareholder support provide a more optimistic long-term view.

Benchmark Holdings (BMK) vs. iShares MSCI United Kingdom ETF (EWC)

Benchmark Holdings Business Overview & Revenue Model

Company DescriptionBenchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, rest of the Europe, and internationally. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products to the aquaculture market. Benchmark Holdings plc was founded in 2000 and is based in Sheffield, the United Kingdom.
How the Company Makes MoneyBenchmark Holdings generates revenue through the sale of its products and services across its three main sectors. In the Genetics sector, the company makes money by providing genetic material and breeding services to enhance the traits of farmed fish, which can lead to higher yields and better resistance to disease. The Advanced Nutrition sector contributes to revenue through the sale of high-performance diets and nutrition products designed to improve the growth and health of farmed fish. In the Health sector, Benchmark earns income from the development and sale of vaccines, medicines, and health management solutions that help prevent and treat diseases in aquaculture. Additionally, Benchmark collaborates with various industry stakeholders and partners to enhance its product offerings and expand its market reach, thus contributing to its overall earnings.

Benchmark Holdings Financial Statement Overview

Summary
Benchmark Holdings presents a mixed financial picture. Despite a healthy equity position and improved cash flow management, ongoing operational losses and declining revenues are concerning. Strategic actions are needed to enhance financial stability.
Income Statement
45
Neutral
Benchmark Holdings has experienced fluctuating revenues, with a significant decline in the TTM period. The gross profit margin has deteriorated from prior years, and while there was a significant net income in the TTM period, it may be due to extraordinary items rather than operational efficiency. EBIT and EBITDA margins are negative, indicating ongoing operational challenges.
Balance Sheet
55
Neutral
The company maintains a healthy equity position with a debt-to-equity ratio that suggests manageable leverage. However, the equity ratio has decreased over the years, reflecting increased liabilities. The TTM shows an improvement in cash positions, which enhances liquidity, but declining total assets over time could be concerning.
Cash Flow
60
Neutral
Benchmark Holdings has improved its free cash flow in the TTM period, indicating better cash management. The operating cash flow to net income ratio suggests the company is generating cash efficiently relative to its reported income. However, consistent negative free cash flow in prior periods indicates past difficulties in generating cash.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue50.77M90.36M169.48M158.28M125.06M105.56M
Gross Profit24.26M43.95M86.75M83.13M65.58M54.96M
EBITDA-2.81M3.96M34.20M28.35M24.36M14.34M
Net Income46.00M-39.46M-23.15M-30.45M-11.58M-22.77M
Balance Sheet
Total Assets424.29M384.90M471.30M526.57M481.99M489.04M
Cash, Cash Equivalents and Short-Term Investments207.51M23.09M36.52M36.40M39.46M71.61M
Total Debt81.61M72.07M102.00M110.14M120.39M109.16M
Total Liabilities121.45M160.63M188.68M203.29M202.39M193.59M
Stockholders Equity302.83M218.26M276.40M313.40M271.71M289.13M
Cash Flow
Free Cash Flow2.54M-1.92M13.22M-1.91M-16.93M-15.47M
Operating Cash Flow6.81M2.00M20.00M10.81M5.79M-4.06M
Investing Cash Flow180.44M-2.83M-5.27M-11.22M-23.09M30.38M
Financing Cash Flow67.00K-10.97M-12.33M-6.92M-14.67M30.13M

Benchmark Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price20.45
Price Trends
50DMA
23.96
Negative
100DMA
23.38
Negative
200DMA
28.39
Negative
Market Momentum
MACD
-0.31
Positive
RSI
17.91
Positive
STOCH
59.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BMK, the sentiment is Negative. The current price of 20.45 is below the 20-day moving average (MA) of 24.27, below the 50-day MA of 23.96, and below the 200-day MA of 28.39, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 17.91 is Positive, neither overbought nor oversold. The STOCH value of 59.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BMK.

Benchmark Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
£181.44M33.675.04%190.84%-0.17%592.46%
63
Neutral
£72.35M99.151.00%
62
Neutral
£51.84M30.721.99%-4.37%
59
Neutral
$355.92M-5.04%-1.02%67.70%
54
Neutral
£172.24M
53
Neutral
£386.08M-369.20%4.50%74.32%
52
Neutral
kr5.63B10.38-63.86%1.96%27.11%26.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:BMK
Benchmark Holdings
20.45
-17.55
-46.18%
GB:AGY
Allergy Therapeutics
8.00
3.20
66.67%
GB:APH
Alliance Pharma
64.70
27.20
72.53%
GB:ANCR
Animalcare
262.00
-6.76
-2.52%
GB:EAH
Eco Animal Health
76.00
-28.50
-27.27%
GB:VLG
Venture Life
58.50
10.25
21.24%

Benchmark Holdings Corporate Events

Delistings and Listing ChangesStock BuybackBusiness Operations and Strategy
Benchmark Holdings Completes Tender Offer, Cancels Shares
Neutral
Jul 25, 2025

Benchmark Holdings announced the results of its Tender Offer, where 127,720,171 Ordinary Shares were purchased and will be canceled, returning approximately £31.9 million to shareholders. This move is part of Benchmark’s strategic plan to conclude discussions with Oslo Børs regarding the cancellation of its shares from Euronext Oslo, impacting the company’s trading and shareholder structure.

Delistings and Listing ChangesExecutive/Board ChangesBusiness Operations and Strategy
Benchmark Holdings Announces Strategic Board and Management Changes
Neutral
Jul 21, 2025

Benchmark Holdings has announced significant changes to its board and management, effective from mid to late August 2025. Patrick Waty will take over as CEO, and Pierre Hugo will become CFO, among other board changes. These shifts are part of a strategic move following the company’s anticipated de-listing, potentially impacting its operational focus and stakeholder dynamics.

Delistings and Listing ChangesBusiness Operations and Strategy
Benchmark Holdings Announces Strategic Delisting and Tender Offer
Neutral
Jul 1, 2025

Benchmark Holdings has announced the approval of its proposals to return the majority of net proceeds from the sale of its Genetics Business to shareholders, delist from AIM and Euronext Growth Oslo, and re-register as a private limited company. The tender offer will open on July 3, 2025, and the delisting from Euronext Growth Oslo is expected to follow the completion of the tender offer. These strategic moves are aimed at streamlining operations and focusing on core business areas, potentially impacting shareholders and market positioning.

Regulatory Filings and Compliance
Benchmark Holdings Updates Total Voting Rights
Neutral
Jun 30, 2025

Benchmark Holdings PLC, a company involved in the aquaculture industry, announced that its total issued share capital now consists of 742,423,113 ordinary shares, all with voting rights. This increase in share capital is attributed to the routine exercise of options by current and former employees under the company’s block admission, impacting the calculation of shareholder interests.

Regulatory Filings and Compliance
Benchmark Holdings Updates Total Voting Rights
Neutral
Jun 30, 2025

Benchmark Holdings PLC, a company involved in the aquaculture industry, announced that as of June 30, 2025, its total issued share capital consists of 742,423,113 ordinary shares, all with voting rights. This increase in share capital is attributed to the routine exercise of options by current and former employees under the company’s block admission. The updated share capital figure will be used by shareholders to determine their interest or changes in their interest in the company.

Delistings and Listing ChangesShareholder MeetingsBusiness Operations and Strategy
Benchmark Holdings Secures Shareholder Approval for Strategic Resolutions
Positive
Jun 18, 2025

Benchmark Holdings announced that all resolutions at their General Meeting were approved, including a tender offer, de-listing, and re-registration. This approval signifies strong shareholder support and could impact the company’s strategic direction and market presence. Additionally, the company was informed of a recapitalization arrangement involving Mavenir Systems Inc., where the Chair of Benchmark, Nathan ‘Tripp’ Lane, is a board director.

Delistings and Listing ChangesM&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Benchmark Holdings Reports £76m Profit, Plans Delisting and Capital Return
Positive
Jun 12, 2025

Benchmark Holdings reported a £76 million profit for the first half of 2025, primarily driven by the £90.9 million gain from the sale of its Genetics business. The company plans to return capital to shareholders and delist from AIM and Euronext Growth Oslo. Despite a 22% decline in group revenues from continuing activities, the company has shown improvements in Advanced Nutrition and maintained solid performance in its Health segment. The restructuring following the Genetics sale is expected to streamline operations and reduce costs, positioning Benchmark for future growth. The company is also preparing for the relaunch of Ectosan® Vet and CleanTreat® with a new land-based model.

Financial Disclosures
Benchmark Holdings Adjusts Webcast Timing for Interim Results Announcement
Neutral
Jun 6, 2025

Benchmark Holdings plc has announced a change in the timing of its Equity Development webcast for retail investors, which will now occur at 10.00am UK time on Thursday, 12 June 2025. This webcast is part of the company’s release of its unaudited interim results for the six-month period ending 31 March 2025. The change in schedule reflects the company’s commitment to engaging with its investors and stakeholders, potentially impacting investor relations and market perception.

Financial Disclosures
Benchmark Holdings to Announce Interim Results on 12 June 2025
Neutral
May 27, 2025

Benchmark Holdings plc has announced that it will release its unaudited interim results for the six-month period ending 31 March 2025 on 12 June 2025. The announcement will be accompanied by presentations for analysts, institutional investors, retail investors, and wealth managers, indicating the company’s commitment to transparency and engagement with its stakeholders.

Delistings and Listing ChangesM&A TransactionsDividendsBusiness Operations and Strategy
Benchmark Holdings Announces Strategic Shift Post-Genetics Business Sale
Neutral
May 23, 2025

Benchmark Holdings PLC has announced a series of proposals following the disposal of its Genetics Business, including the return of capital to shareholders and the cancellation of its shares from trading on AIM and Euronext Growth Oslo. The company plans to re-register as a private limited company and offer a tender for shareholders to realize their investments, with a special dividend planned post-tender. These moves aim to streamline operations and focus on future growth, with implications for shareholder structure and market presence.

Other
Benchmark Holdings Confirms Stable Share Capital Structure
Positive
Apr 30, 2025

Benchmark Holdings PLC announced that as of 30 April 2025, its issued share capital consists of 741,505,672 ordinary shares, all with voting rights. This figure has remained unchanged since the previous announcement on 31 March 2025, and shareholders can use this number to calculate their interest in the company. This stability in share capital indicates a steady state in the company’s financial structure, which could reassure investors and stakeholders about the company’s current market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025